Why Rheumatologists Are Rebranding as 'Autoimmunologists' and What It Means for Your Care
The medical specialty treating autoimmune diseases is undergoing a quiet but significant identity shift, with leading physicians arguing that the term 'rheumatology' no longer captures the complexity of what they actually treat. Diseases like systemic lupus erythematosus (SLE), multiple sclerosis (MS), and rheumatoid arthritis can devastate the brain, heart, kidneys, and skin, yet the field's name suggests it only deals with joint and muscle inflammation. This disconnect is prompting experts to advocate for renaming the specialty to better reflect modern medicine .
What's Wrong With the Term 'Rheumatology'?
The word "rheumatology" comes from an outdated concept of rheumatism, which historically referred to inflammation in joints and muscles. However, the diseases rheumatologists treat today are far more complex and potentially life-threatening. Systemic lupus erythematosus, for example, can attack virtually any organ in the body, making it a multi-system disease rather than a joint-focused condition. Other autoimmune conditions like multiple sclerosis target the brain and nervous system, while Crohn's disease affects the digestive tract, and Hashimoto's disease targets the thyroid. The current terminology fails to communicate the true scope of these conditions to patients, families, and even medical students .
This naming issue has real consequences. When patients hear "rheumatology," they often expect to see a specialist focused on arthritis. Young people diagnosed with lupus may not realize they're seeing a rheumatologist because the connection between their multi-organ disease and joint inflammation isn't obvious. The terminology gap can delay understanding and engagement with treatment .
Why Are Experts Pushing for 'Autoimmunology' Instead?
The proposed alternative, "autoimmunology," directly describes what the specialty actually addresses: conditions where the immune system malfunctions and attacks the body's own tissues. This terminology accurately reflects the core mechanism of diseases treated by these specialists. The immune system normally functions like the body's army, defending against external invaders such as bacteria and viruses. In autoimmune conditions, this protective system becomes confused and mounts an attack against the body itself. Understanding this fundamental mechanism is crucial for patients and trainees alike .
Leading specialists in the field believe this rebranding would improve patient education, attract more talented physicians to the specialty, and better position the field within modern medicine. The change also acknowledges that treating autoimmune diseases requires deep expertise in immunology, not just rheumatology. Specialists in this field must understand how the immune system works and, critically, how and why it malfunctions .
How Are Treatment Options Evolving for Autoimmune Diseases?
The landscape of autoimmune disease treatment is expanding rapidly, with new medications specifically designed to target the immune mechanisms responsible for self-attack. As of March 2026, several promising treatments are in advanced development stages. These targeted therapies represent a significant shift from older, less specific treatments that suppressed the entire immune system. The new generation of drugs is designed to be more precise, addressing the specific immune pathways that go wrong in each condition .
Recent drug pipeline updates show multiple investigational treatments advancing through clinical trials for autoimmune conditions:
- Nipocalimab (Johnson & Johnson): A neonatal Fc receptor blocker designed to treat active systemic lupus erythematosus, currently receiving Fast Track designation to accelerate development and approval .
- Brepocitinib (Priovant): A tyrosine kinase 2 and Janus kinase 1 inhibitor for treating dermatomyositis, an autoimmune condition affecting muscles and skin, currently in Priority Review .
- Fenebrutinib (Genentech): A Bruton tyrosine kinase inhibitor for relapsing multiple sclerosis that recently completed Phase 3 clinical trials .
These medications represent a fundamental change in how autoimmune diseases are approached. Rather than broadly suppressing immune function, they target specific pathways involved in the autoimmune attack. This precision approach offers the potential for better efficacy with fewer side effects compared to older treatments .
What Does This Mean for Patients With Autoimmune Conditions?
The combination of improved terminology and advancing treatment options suggests a brighter future for patients with autoimmune diseases. Specialists in the field note that medications available in 2026 are "rapidly growing and more effective than ever," with many specifically designed to target the immune mechanisms responsible for the attack against self . This represents genuine progress for conditions that were once considered devastating and difficult to manage.
The push to rebrand the specialty as autoimmunology also signals a cultural shift within medicine. It acknowledges that autoimmune diseases are serious, multi-system conditions requiring sophisticated understanding of immunology. For patients, this means their conditions are being taken seriously by specialists who are investing in both research and education to improve outcomes. Young people diagnosed with lupus, for example, now have access to treatments that were unavailable to previous generations, offering hope for better long-term health outcomes .
The field's evolution reflects a broader recognition that autoimmune diseases deserve the same level of attention and resources as other serious medical conditions. As specialists continue to advocate for better terminology and develop more targeted treatments, patients can expect improved understanding of their conditions and access to increasingly effective therapies designed specifically for autoimmune mechanisms.